
Using Relacorilant Plus Nab-Paclitaxel Earlier in Platinum Resistance
Rachel N. Grisham, MD, of Memorial Sloan Kettering Cancer Center, and Ritu Salani, MD, MBA, of the David Geffen School of Medicine at UCLA, consider whether the immune effects of relacorilant argue for using it earlier in platinum-resistant ovarian cancer.
Episodes in this series

Rachel N. Grisham, MD, of Memorial Sloan Kettering Cancer Center, and Ritu Salani, MD, MBA, of the David Geffen School of Medicine at UCLA, consider whether the immune effects of relacorilant argue for using it earlier in platinum-resistant ovarian cancer. Grisham admits that when relacorilant plus nab-paclitaxel was first approved she gave it to patients in later lines so they would not miss out. She now prioritizes it within the first 3 lines of therapy, where the data are strongest, cumulative toxicity is lower, and immune-based treatment tends to work best. The two compare bevacizumab use, since prior bevacizumab was required in the trial; Grisham uses it in about 20% of frontline patients and at first platinum-sensitive recurrence, while Salani uses it more often, especially for patients without BRCA mutations or homologous recombination deficiency. Salani favors the regimen for patients platinum resistant right after carboplatin and paclitaxel and routinely adds G-CSF support.
Related to this article








